Portfoliotracker

Egetis Therapeutics AB (publ)

EGTX.ST · STOCKHOLM · Healthcare Biotechnology 3/100 E

11,12 SEK
▲ +0,00 (+0,00 %)
Trading
Price as of 17. 11. 13:45, fetched 17. 11. 13:48
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score3 / 100 Market cap5,07 mld. SEK P/E– Forward P/E92,7 P/S76,7 P/B10,5 EV/EBITDA– Dividend yield– FCF yield-5,94 % EPS-1,10 SEK Net margin0,0 % Return on equity-152,2 % Beta0,81 Debt / equity0,22
52-week range 3,63 to 11,20
3-month average volume3,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

Website
egetis.com
Employees
61
Country
Sweden
Data since
7. 4. 2011

Explore further

Similar companies HNSA.STVICO.STONCO.STBIOA-B.ST

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account